These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39410032)

  • 21. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
    Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
    Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
    Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
    J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
    Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. F-18 FDG PET/CT in the management of thyroid cancer.
    Iagaru A; Kalinyak JE; McDougall IR
    Clin Nucl Med; 2007 Sep; 32(9):690-5. PubMed ID: 17710020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
    Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
    Ma C; Xie J; Liu W; Wang G; Zuo S; Wang X; Wu F
    Cochrane Database Syst Rev; 2010 Nov; 2010(11):CD008302. PubMed ID: 21069705
    [TBL] [Abstract][Full Text] [Related]  

  • 29.
    Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
    Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
    [No Abstract]   [Full Text] [Related]  

  • 30. Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Endocr Pract; 2013; 19(1):139-48. PubMed ID: 23186979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
    David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
    Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.
    Bombardieri E; Seregni E; Villano C; Aliberti G; Mattavelli F
    Tumori; 2003; 89(5):533-6. PubMed ID: 14870779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
    Podoba J
    Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
    Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
    Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant human TSH in radioiodine treatment of differentiated thyroid cancer.
    Kovatcheva RD; Hadjieva TD; Kirilov GG; Lozanov BS
    Nucl Med Rev Cent East Eur; 2004; 7(1):13-9. PubMed ID: 15318305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine.
    Kohlfuerst S; Igerc I; Lind P
    Thyroid; 2005 Apr; 15(4):371-6. PubMed ID: 15876162
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
    Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
    Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incremental diagnostic value of [
    Dittmann M; Gonzalez Carvalho JM; Rahbar K; Schäfers M; Claesener M; Riemann B; Seifert R
    Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2639-2646. PubMed ID: 32248325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting
    Liu M; Cheng L; Jin Y; Ruan M; Sheng S; Chen L
    Sci Rep; 2018 Mar; 8(1):4352. PubMed ID: 29531251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
    Kukulska A; Krajewska J; Kołosza Z; Paliczka-Cies Lik E; Puch Z; Gubała E; Król A; Kalemba M; Kropin Ska A; Jarząb B
    Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.